<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00244881</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02937</org_study_id>
    <secondary_id>05-160</secondary_id>
    <secondary_id>U01CA062490</secondary_id>
    <secondary_id>CDR0000445438</secondary_id>
    <nct_id>NCT00244881</nct_id>
    <nct_alias>NCT00215488</nct_alias>
  </id_info>
  <brief_title>A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)</brief_title>
  <official_title>A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      AZD2171 (cediranib maleate) may stop the growth of tumor cells by blocking some of the
      enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial
      is studying how well AZD2171 works in treating patients with refractory stage IV breast
      cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Evaluation of the fraction of patients with increased levels of circulating endothelial
      cells after 3 weeks of treatment with AZD2171.

      II. Estimation of the objective response rate (ORR = CR + PR) among patients with refractory
      breast cancer receiving AZD2171.

      SECONDARY OBJECTIVES:

      I. Estimation of the response/stable disease rate (RSDR = CR + PR + SD). II. Characterization
      of the toxicity associated with AZD2171 in this cohort of patients.

      III. Analyses to correlate serial quantification of circulating endothelial cells and
      circulating tumor cells with traditional clinical endpoints including RR and TTP.

      IV. Develop pharmacodynamic measures of AZ2171 activity based on monocyte count and VEGFR-1
      phosphorylation within monocytes.

      OUTLINE: This is a nonrandomized, open-label, multicenter study.

      Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the
      absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed for 3 months.

      PROJECTED ACCRUAL: A total of 26 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fraction of Patients With Increased Levels of Circulating Endothelial Cells</measure>
    <time_frame>After 3 weeks of treatment</time_frame>
    <description>An exact 95% confidence interval (CI) will be calculated for the CEC response rate. With 26 patients, this CI will be no wider than 40% (e.g., if 13 of 26 patients respond, the CI is 30% to 70%).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR = CR + PR) Classified According to RECIST Criteria</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>RECIST 1.0 Criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response/Stable Disease Rate Defined as the Percentage of Patients Demonstrating CR + PR + SD</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Male Breast Cancer</condition>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (cediranib maleate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cediranib maleate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (cediranib maleate)</arm_group_label>
    <other_name>AZD2171</other_name>
    <other_name>Recentin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (cediranib maleate)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed Breast Cancer, stage IV,
             including:

               -  &quot;Breast neoplasms malignant and unspecified (incl nipple)&quot;,&quot;Breast and nipple
                  neoplasms malignant&quot;,&quot;Breast cancer stage IV&quot;,&quot;10006202&quot;

               -  Breast neoplasms malignant and unspecified (incl nipple)&quot;,&quot;Breast and nipple
                  neoplasms malignant&quot;,&quot;Breast cancer recurrent&quot;,&quot;10006198&quot;

               -  &quot;Breast neoplasms malignant and unspecified (incl nipple)&quot;,&quot;Breast and nipple
                  neoplasms malignant&quot;,&quot;Inflammatory carcinoma of breast stage IV&quot;,&quot;10021979&quot;

          -  Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded) as &gt;=
             20 mm with conventional techniques or as &gt;= 10 mm with spiral CT scan

          -  Patients must have refractory breast cancer, defined as overt clinical tumor
             progression on most recent treatment with either hormonal therapy, chemotherapy,
             and/or trastuzumab therapy; patients with up to 3 prior chemotherapy regimens and with
             any number of biological (hormonal, trastuzumab) regimens for metastatic breast cancer
             will be eligible

          -  Life expectancy of greater than 3 months as assessed by the patient's primary
             oncologist

          -  Absolute neutrophil count &gt; 1,500/mcL

          -  Platelets &gt; 100,000/mcL

          -  Hemoglobin &gt;= 8 g/dL

          -  Prothrombin time &lt; institutional upper limit of normal (ULN)

          -  Total bilirubin =&lt; 1.5 x ULN

          -  AST(SGOT)/ALT(SGPT) =&lt; 2.5 Ã— ULN

          -  Creatinine within normal institutional limits

          -  Urinalysis with &lt; 1+ proteinuria

          -  Troponin T or I within normal institutional limits

          -  LVEF &gt;= 45%, as assessed by echocardiogram or nuclear medicine gated study, within 30
             days prior to initiating protocol-based treatment

          -  At present, the potential of AZD2171 for clinically significant drug interactions
             involving the CYP isozymes is unknown; however, studies of the agent in rats indicated
             possible suppression of CYP1A that may be of biological significance; eligibility of
             patients receiving any medications or substances known to affect or with the potential
             to affect the activity or PK of AZD2171 will be determined following review of their
             case by the Principal Investigator.

          -  AZD2171 has been shown to terminate fetal development in the rat, as expected for a
             process dependent on VEGF signaling; for this reason, women of child-bearing potential
             must have a negative pregnancy test prior to study entry; women of child-bearing
             potential and men must agree to use adequate contraception (hormonal or barrier method
             of birth control; abstinence) prior to study entry and for the duration of study
             participation; should a woman become pregnant or suspect she is pregnant while
             participating in this study, she should inform her treating physician immediately

          -  No therapeutic anti-coagulation; the use of low dose warfarin (1-2 mg/day),
             intermittent doses of TPA (2 mg x 1), or heparin flushes to prophylax against central
             venous catheter-associated clots is acceptable

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients who have had chemotherapy, radiotherapy, or major surgery within 4 weeks (6
             weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have
             not recovered from adverse events due to agents administered more than 4 weeks earlier

          -  Patients may not be receiving any other investigational agents nor have participated
             in an investigational trial within the past 30 days

          -  Patients may not have been previously treated with an anti-angiogenesis agent

          -  \Patients may not be receiving any medication that may markedly affect renal function
             (e.g., vancomycin, amphotericin, pentamidine); these medications will also not be
             permitted after the start of the study

          -  Patients with known brain metastases should be excluded from this clinical trial
             because of their poor prognosis and because they often develop progressive neurologic
             dysfunction that would confound the evaluation of neurologic and other adverse events;
             a head CT or MRI must be performed at baseline

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to AZD2171

          -  Any contraindications/barrier to oral medication

          -  EKG abnormalities of known clinical significance, such as prolonged QT (mean QTc &gt; 470
             msec, with Bazett's correction, in screening electrocardiogram or history of familial
             long QT syndrome); an EKG is required for study entry

          -  Uncontrolled intercurrent illness including, but not limited to hypertension, ongoing
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,
             cardiac arrhythmia, or psychiatric illness/social situations that would limit
             compliance with study requirements

          -  Pregnant women are excluded from this study because AZD2171 is a VEGF inhibitor with
             known abortifacient effects; because there is an unknown but potential risk for
             adverse events in nursing infants secondary to treatment of the mother with AZD2171,
             breastfeeding should be discontinued if the mother is treated with AZD2171

          -  HIV-positive patients on combination antiretroviral therapy are ineligible because of
             the potential for pharmacokinetic interactions with AZD2171; appropriate studies will
             be undertaken in patients receiving combination antiretroviral therapy when indicated

          -  Patients at increased risk for compromised LVEF requiring concurrent use of drugs or
             biologics with proarrythmic potential; these drugs are prohibited during studies with
             AZD2171 (refer to Appendix J for a listing of these agents)

          -  Patients with a New York Heart Association classification of III or IV are excluded
             (NOTE: patients classified as class II are eligible if controlled on medication and
             stable with increased monitoring)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harold Burstein</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2005</study_first_submitted>
  <study_first_submitted_qc>October 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2005</study_first_posted>
  <results_first_submitted>November 4, 2013</results_first_submitted>
  <results_first_submitted_qc>November 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 23, 2013</results_first_posted>
  <last_update_submitted>December 3, 2015</last_update_submitted>
  <last_update_submitted_qc>December 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maleic acid</mesh_term>
    <mesh_term>Cediranib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at Dana-Farber/Harvard Cancer Center</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Cediranib Maleate)</title>
          <description>Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Cediranib Maleate)</title>
          <description>Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.3" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fraction of Patients With Increased Levels of Circulating Endothelial Cells</title>
        <description>An exact 95% confidence interval (CI) will be calculated for the CEC response rate. With 26 patients, this CI will be no wider than 40% (e.g., if 13 of 26 patients respond, the CI is 30% to 70%).</description>
        <time_frame>After 3 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cediranib Maleate)</title>
            <description>Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Fraction of Patients With Increased Levels of Circulating Endothelial Cells</title>
          <description>An exact 95% confidence interval (CI) will be calculated for the CEC response rate. With 26 patients, this CI will be no wider than 40% (e.g., if 13 of 26 patients respond, the CI is 30% to 70%).</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate (ORR = CR + PR) Classified According to RECIST Criteria</title>
        <description>RECIST 1.0 Criteria</description>
        <time_frame>Up to 7 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cediranib Maleate)</title>
            <description>Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR = CR + PR) Classified According to RECIST Criteria</title>
          <description>RECIST 1.0 Criteria</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="1" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response/Stable Disease Rate Defined as the Percentage of Patients Demonstrating CR + PR + SD</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cediranib Maleate)</title>
            <description>Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Response/Stable Disease Rate Defined as the Percentage of Patients Demonstrating CR + PR + SD</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Cediranib Maleate)</title>
          <description>Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left Ventricular Systolic Dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Gallbladder Abnormality</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>LFT Abnormalities</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>LV systolic dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Esophagitis/Mucositis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Harold Burstein</name_or_title>
      <organization>Dana-Farber Cancer Institute</organization>
      <phone>617-632-3800</phone>
      <email>hburstein@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

